PharmaVoice

OCTOBER 1, 2024

Mark your calendars for the most important industry conferences in 2025.

Pharma 101

Pharma 101

Pharma Marketing Network

NOVEMBER 1, 2024

The world of pharma marketing is changing rapidly, and 2025 will be no exception. So, what will be the top challenges in 2025, and how can pharma marketers tackle them? Data Privacy and Compliance Challenges Data privacy is one of the most pressing concerns in 2025, especially with new regulations being enacted globally.

Marketing 52

Marketing Pharma Ethics Healthcare Provider 52

PharmExec

OCTOBER 22, 2024

In this part of her video interview, Amanda Powers-Han, Chief Marketing Officer, Greater Than One and Pharmaceutical Executive Advisory Board Member identifies marketing trends you expect to be big right away in 2025.

Marketing 52

Marketing Pharma Pharmaceutical 52

Fierce Pharma

OCTOBER 31, 2024

billion restructuring initiative that runs through 2025 may not be the end of the company’s ongoing efficiency push. | Bristol Myers' $1.5 billion restructuring initiative that runs through 2025 may not be the end of the company's ongoing efficiency push. Bristol Myers’ $1.5

282

282

MedCity News

OCTOBER 27, 2024

The post NCQA’s Updated 2025 Standards Have Published: What it Means for Quality and Compliance in Healthcare appeared first on MedCity News.

Healthcare 92

Healthcare Healthcare 92

Pharmaceutical Commerce

NOVEMBER 4, 2024

With a 26% decline in prescription drug plans from 2024 to 2025, navigating potential gaps and accessing care remains vital for low income patients.

Prescription 52

Prescription Patients 52

Eversana Intouch

NOVEMBER 18, 2024

In this report, 15 of our experts examine the current impact of each of these three forces, predict how you’ll see their effects in 2025 and give recommendations for how to make these market forces work for you. Over the coming weeks, you’ll be seeing a lot of forecasts for 2025. And this isn’t an anonymous think piece.

Marketing 52

Marketing Pharma Competition Patients 52

PM360

NOVEMBER 12, 2024

The 2025 Healthcare CMO Summit is an exclusive invitation-only event designed to bring together Chief Medical Officers (CMOs) and innovative suppliers and solution providers. Scheduled for February 3-4, 2025 , at The Ritz-Carlton Dallas, Las Colinas , the summit will address key clinical healthcare challenges and relevant market developments.

Medical 52

Medical Healthcare Healthcare Safety 52

PM360

NOVEMBER 12, 2024

The 2025 Healthcare CNO Summit , an exclusive invitation-only event, is scheduled for February 3-4, 2025, at The Ritz-Carlton Dallas, Las Colinas. The summit will focus on critical topics essential to the nursing profession, including: CNE Leadership Role: Examining the essential skill set that impacts nursing leadership.

Healthcare 52

Healthcare Healthcare Safety Networking 52

Contrarian Sales Techniques

OCTOBER 19, 2024

Malaysia’s Budget 2025 is out, on October 18th 2024, and it’s packed with changes that will touch nearly every aspect of your lives and mine, from salaries to taxes, and even our environment. Now, before you celebrate, this change kicks in February 2025, so we have to wait a bit. Let me know your thoughts on Budget 2025.

Medical sales 52

Medical sales Medical sales reps Government Ethics 52

Fierce Pharma

SEPTEMBER 12, 2024

Gilead Sciences is no stranger to making history in HIV. | In a study of more than 3,000 participants, Gilead's twice-yearly lenacapavir delivered a 96% reduction in HIV infections compared with background HIV incidence.

315

315

Pharmaceutical Commerce

OCTOBER 16, 2024

Plus, get a sneak peek into the exciting plans for LogiPharma's 20th Anniversary in 2025. From attendee feedback to the most impactful sessions, Ryan shares insider insights and discusses how the momentum from 2024 will continue to shape the future of pharma supply chains.

Specialization 52

Specialization Pharma 52

Tribeca Knowledge

OCTOBER 1, 2024

M arket Access 2025, a new report from TRiBECA Knowledge, offers a fresh perspective on how the market access landscape for medicines continues to raise the bar for launch success and consistently better patient outcomes.

Marketing 52

Marketing Medicine Patients 52

Fierce Pharma

AUGUST 9, 2024

With Gilead's stated focus to grow in oncology, the company's recent quarterly updates have placed a heavy emphasis on its developments in the cancer space. | The HIV-focused drugmaker looks to position its long-acting Sunlenca as a prime PrEP option after the med aced a phase 3 study.

Marketing 283

Marketing 283

Pharma Marketing Network

OCTOBER 17, 2024

As we approach 2025, the ability of pharmaceutical companies to effectively craft and communicate their brand identity will play a pivotal role in determining their market success. Key Strategies for Pharma Marketing in 2025 As pharmaceutical companies look to 2025, embracing a patient-centric approach will be pivotal.

Healthcare 52

Healthcare Healthcare Marketing Pharma 52

Fierce Pharma

OCTOBER 29, 2024

Incyte’s blockbuster JAK inhibitor Jakafi has been driving the company’s sales for years now, with this quarter being no different. Meanwhile, the company also scrapped plans to expand its topical JAK Opzelura into two other skin disorders.

Sales 238

Sales 238

Nixon Gwilt Law

NOVEMBER 8, 2024

CMS issued its 2025 Medicare Physician Fee Schedule (the “2025 MPFS” or “Final Rule”) on November 1, 2024. The Final 2025 MPFS contains some modifications and clarifications to several elements of the original proposal released in July 2024 (the “Proposed Rule”), which we discussed in this earlier post.

FDA 52

FDA Physicians Management Patients 52

Nixon Gwilt Law

NOVEMBER 8, 2024

CMS issued its 2025 Medicare Physician Fee Schedule (the “2025 MPFS” or “Final Rule”) on November 1, 2024. The Final 2025 MPFS contains some modifications and clarifications to several elements of the original proposal released in July 2024 (the “Proposed Rule”), which we discussed in this earlier post.

FDA 52

FDA Physicians Management Patients 52

pharmaphorum

OCTOBER 5, 2023

Moderna eyes 2025 approval for COVID, flu combination jab Phil.Taylor Thu, 05/10/2023 - 08:38 Bookmark this

98

98

Pharma Marketing Network

NOVEMBER 15, 2024

But with tight budgets and an evolving landscape, how can pharma professionals effectively connect in 2025 without breaking the bank? Leverage Virtual Platforms The pandemic taught us the power of virtual connectivity, and in 2025, this trend continues. Let’s dive into ten strategies that are both impactful and affordable.

Networking 52

Networking Pharma Marketing CRM 52

Nixon Gwilt Law

NOVEMBER 14, 2024

In a significant move to incentivize enhanced primary care delivery and management, the Centers for Medicare & Medicaid Services (CMS) have finalized the Advanced Primary Care Management (APCM) codes in the 2025 Medicare Physician Fee Schedule (the” 2025 Final MPFS” or the “Final Rule”). Contact us today via this page.

Physicians 52

Physicians Management Healthcare Healthcare 52

PharmaTech

AUGUST 9, 2024

The program, for which visits will be scheduled through September 2025, does not replace or supplement a regulatory inspection.

FDA 52

FDA 52

Pharma Marketing Network

OCTOBER 17, 2024

As we approach 2025, the pharmaceutical industry is witnessing a seismic shift in marketing strategies, driven by technological advancements and evolving consumer expectations. As we move towards 2025, regulatory bodies are increasingly focusing on transparency, patient privacy, and ethical marketing practices.

Marketing 52

Marketing Healthcare Healthcare Pharma 52

Pharmacy Times

SEPTEMBER 6, 2024

New transparency initiatives will go into effect on January 1, 2025, building off previous actions by the Centers of Medicare and Medicaid Services.

52

52

Fierce Pharma

MAY 28, 2024

A recently announced $900 million restructuring drive is already making waves at Takeda, wi | From early July to March 2025, the Japanese drugmaker will cut 495 staffers at its Cambridge location and 146 in Lexington, Massachusetts. Takeda is the largest life sciences employer in the state.

329

329

pharmaphorum

JULY 8, 2022

That spend is due to reach of $3 billion by 2025, according to GlobalData analyst Kitty Whitney, who notes that there has been a steady stream of startups formed in the last three to four years to tap into the emerging AI market. The post Pharma’s spend on AI in drug discovery ‘could top $3bn by 2025’ appeared first on.

Marketing 127

Marketing Pharma Education Medicine 127

PharmaTech

OCTOBER 31, 2024

Alec McChesney (BD Director, SCORR Marketing) discusses goal setting and alignment between life sciences marketing and business development teams.

Marketing 52

Marketing 52

Fierce Pharma

APRIL 23, 2024

The recent Big Pharma CEO, known for steering the $74 billion acquisition of Celgene, has been proposed as the new chair at Novartis for 2025. . | Giovanni Caforio, M.D., is lining up a new gig soon after handing all his Bristol Myers Squibb leadership roles in March.

Pharma 338

Pharma 338

Pharmaceutical Commerce

JANUARY 10, 2024

At the 42nd annual JP Morgan Healthcare Conference, Moderna said new product launches later this year will return the company to sales growth in 2025.

Sales 52

Sales Healthcare Healthcare 52

Fierce Pharma

AUGUST 26, 2024

When CVS Caremark removed AbbVie’s Humira from its national commercial formularies back in April, biosimilar prescriptions picked up at a whirlwind pace. Following CVS Caremark's lead, Cigna's pharmacy benefit manager unit will nix Humira from formularies in favor of Humira biosimilars from Boehringer Ingelheim, Teva and Sandoz.

Prescription 220

Prescription Management Leads 220

Fierce Pharma

JUNE 12, 2023

market without a patent infringement challenge by early 2025 thanks to a new settlement. 21, 2025. Another biosimilar product copying Johnson & Johnson’s top-selling drug Stelara may enter the U.S. Following a deal with Amgen, J&J has granted Alvotech and Teva a license to launch their Stelara biosimilar no later than Feb.

Marketing 272

Marketing 272

Fierce Pharma

AUGUST 7, 2024

In its quarterly earnings presentation, the Danish company said that after discussions with the FDA, it has pulled its filing and expects to resubmit in early 2025. . | Novo Nordisk’s attempt to gain an approval to treat heart failure patients with its obesity drug Wegovy has been put on hold.

FDA 264

FDA Patients 264

Pharmaceutical Technology

DECEMBER 20, 2023

The EC has revoked marketing authorisations for Tecfidera generics, granting the drug marketing protection until February 2025.

Marketing 52

Marketing 52

Fierce Pharma

JUNE 5, 2024

billion in costs by the end of 2025, a company spokesperson said over email. . | Starting this month, BMS will begin the process of laying off around 863 employees in Lawrenceville, New Jersey, according to a Worker Adjustment and Retraining Notification (WARN) alert from the state. The move forms part of BMS’ campaign to shave off $1.5

302

302

Fierce Pharma

OCTOBER 7, 2024

GSK’s ViiV healthcare unit is countering rival HIV drugmaker Gilead’s recent global access moves with its own pledge to make at least 2 million doses of its long-acting pre-exposure prophylaxis (Pr | The long-acting HIV PrEP maker pledged to make at least 2 million more doses available for low-and middle-income countries in 2025 and 2026.

Healthcare 183

Healthcare Healthcare 183

Nixon Gwilt Law

JULY 12, 2024

The 2025 Medicare Physician Fee Schedule Proposed Rule (the “2025 Proposed Rule”) issued by the Centers for Medicare and Medicaid Services (or “CMS”) on July 10, 2024 contains a number of new policy proposals with significant implications for healthcare innovators.

Physicians 52

Physicians Management Food and Drug Administration Healthcare 52

Fierce Pharma

AUGUST 19, 2024

. | The agency granted a broad regulatory exclusivity to rival United Therapeutics and its Tyvasvo DPI, leaving Liquidia's Yutrepia, which uses the same active drug, in FDA limbo until 2025.

FDA 220

FDA 220